Favourable response to rituximab by an ocular adnexal primary lymphoma

Abstract Case report A 70-year-old woman who presented with an extranodal marginal zone B-cell lymphoma in lacrimal gland and conjunctiva. Initial treatment with rituximab yielded an immediate good response. Five months later she showed lymphoid proliferation in her contralateral conjunctiva. Althou...

Full description

Saved in:

Bibliographic Details
Published in:	Archivos de la Sociedad Española de Oftalmología (English ed.) Vol. 91; no. 11; pp. 539 - 542
Main Authors:	Luque Valentin-Fernandez, M.L, Alvarez Rodríguez, F, Rodríguez Jiménez, I
Format:	Journal Article
Language:	English
Published:	Elsevier España, S.L.U 01-11-2016
Subjects:	Conjunctival lymphoma Lacrimal gland lymphoma Linfoma Linfoma de anejos oculares Linfoma de conjuntiva Linfoma de glándula lagrimal Lymphoma Ocular adnexal lymphoma Ophthalmology Rituximab Linfoma de glándula lagrimal Linfoma de conjuntiva Lacrimal gland lymphoma Linfoma de anejos oculares Ocular adnexal lymphoma Rituximab Conjunctival lymphoma Linfoma Lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Case report A 70-year-old woman who presented with an extranodal marginal zone B-cell lymphoma in lacrimal gland and conjunctiva. Initial treatment with rituximab yielded an immediate good response. Five months later she showed lymphoid proliferation in her contralateral conjunctiva. Although no additional treatment was performed, the patient has been free of systemic symptoms and recurrences. Discussion Rituximab is a quite good therapeutic agent in low grade adnexal lymphomas.
ISSN:	2173-5794 2173-5794
DOI:	10.1016/j.oftale.2016.03.007